The FDA issued a warning letter to ProRx, a compounding facility in Exton, Penn., after an inspection raised serious concerns regarding the safety and compliance of its drug products. The facility, which registered as an outsourcing drug compounder in April 2022, was found to have violated several critical provisions under the Federal Food, Drug and Cosmetic Act.
Read the full post on Becker's Hospital Review | Healthcare News & Analysis
